FMI researchers have developed a new tool that maps how proteases—enzymes that process proteins—cut their targets. This innovation offers new insight into the highly selective nature of proteases, which were previously seen as indiscriminate degraders. The work could change how we approach drug design, particularly for conditions such as diabetes and obesity, by creating more stable, targeted treatments.
New tool to map protease specificity may pave the way for improved treatments
